3 Things You (Still) Need to Know About GLP-1 Agonists
Incretin mimetic therapy for type 2 diabetes has been on the market for more than 10 years. Find out what you've learned about the GLP-1 agonists, here.
SUBSCRIBE: eNewsletter
Incretin mimetic therapy for type 2 diabetes has been on the market for more than 10 years. Find out what you've learned about the GLP-1 agonists, here.
The ADA provides an abridged version for PCPs of its annual Standards of Medical Care. Our slides summarize 6 updates important to primary care.
Contrave, a combination of naltrexone and buproprion, has been approved for long-term weight loss management in overweight and obese adults.
Studies looking at add-on treatment with SGLT2 inhibitors show their effects on glycemic control to be roughly additive. Here, a concise look at clinical trial results plus guidance on renal dose adjustment.
Early use of combination therapy to treat type 2 diabetes is shown to limit glucose toxicity and preserve beta-cell function.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.